205 research outputs found
Iron overload in polytransfused patients without heart failure is associated with subclinical alterations of systolic left ventricular function using cardiovascular magnetic resonance tagging
BACKGROUND: It remains incompletely understood whether patients with transfusion related cardiac iron overload without signs of heart failure exhibit already subclinical alterations of systolic left ventricular (LV) dysfunction. Therefore we performed a comprehensive evaluation of systolic and diastolic cardiac function in such patients using tagged and phase-contrast CMR. METHODS: 19 patients requiring regular blood transfusions for chronic anemia and 8 healthy volunteers were investigated using cine, tagged, and phase-contrast and T2* CMR. LV ejection fraction, peak filling rate, end-systolic global midventricular systolic Eulerian radial thickening and shortening strains as well as left ventricular rotation and twist, mitral E and A wave velocity, and tissue e' wave and E/e' wave velocity ratio, as well as isovolumic relaxation time and E wave deceleration time were computed and compared to cardiac T2*. RESULTS: Patients without significant iron overload (T2* > 20 ms, n = 9) had similar parameters of systolic and diastolic function as normal controls, whereas patients with severe iron overload (T2* 20 ms) or normal controls. Patients with moderate iron overload (T2* 10-20 ms, n = 5), had preserved ejection fraction (59 ± 6%, p = NS vs. pts. with T2* > 20 ms and controls), but showed reduced maximal LV rotational twist (1.8 ± 0.4 degrees). The magnitude of reduction of LV twist (r = 0.64, p < 0.001), of LV ejection fraction (r = 0.44, p < 0.001), of peak radial thickening (r = 0.58, p < 0.001) and of systolic (r = 0.50, p < 0.05) and diastolic twist and untwist rate (r = -0.53, p < 0.001) in patients were directly correlated to the logarithm of cardiac T2*. CONCLUSION: Multiple transfused patients with normal ejection fraction and without heart failure have subclinical alterations of systolic and diastolic LV function in direct relation to the severity of cardiac iron overload. Among all parameters, left ventricular twist is affected earliest, and has the highest correlation to log (T2*), suggesting that this parameter might be used to follow systolic left ventricular function in patients with iron overload
High-intensity aerobic interval training and resistance training are feasible in rectal cancer patients undergoing chemoradiotherapy: a feasibility randomized controlled study
Background: There has been growing evidence of the benefits of high-intensity aerobic interval training (HIIT) and resistance training (RES) for populations with cancer. However, these two modalities have not yet been performed alone in rectal cancer patients undergoing neoadjuvant chemoradiotherapy (NACRT). Therefore, this study aimed to determine the feasibility of HIIT and RES in rectal cancer patients undergoing NACRT.
Materials and methods: Rectal cancer patients set to undergo NACRT were randomly assigned to HIIT intervention, RES intervention, or the usual care. Feasibility of HIIT and RES was assessed by measuring recruitment rate, adherence (retention rate, attendance rate, and exercise sessions duration and intensity), and adverse events. Endpoints (changes in fatigue, health-related quality of life, depression, daytime sleepiness, insomnia, sleep quality, functional exercise capacity, and executive function) were assessed at baseline and at week 5.
Results: Among the 20 eligible patients, 18 subjects were enrolled and completed the study, yielding a 90% recruitment rate and 100% retention rate. Attendance at exercise sessions was excellent, with 92% in HIIT and 88% in RES. No exercise-related adverse events occurred. Conclusion: This study demonstrated that HIIT and RES are feasible in rectal cancer patients undergoing NACRT.
Trial registration: www.clinicaltrials.gov, NCT03252821 (date of registration: March 30, 2017)
3D histopathology of stenotic aortic valve cusps using ex vivo microfocus computed tomography
BackgroundCalcific aortic stenosis (AS) is the most prevalent heart valve disease in developed countries. The aortic valve cusps progressively thicken and the valve does not open fully due to the presence of calcifications. In vivo imaging, usually used for diagnosis, does not allow the visualization of the microstructural changes associated with AS.MethodsEx vivo high-resolution microfocus computed tomography (microCT) was used to quantitatively describe the microstructure of calcified aortic valve cusps in full 3D. As case study in our work, this quantitative analysis was applied to normal-flow low-gradient severe AS (NF-LG-SAS), for which the medical prognostic is still highly debated in the current literature, and high-gradient severe AS (HG-SAS).ResultsThe volume proportion of calcification, the size and number of calcified particles and their density composition was quantified. A new size-based classification considering small-sized particles that are not detected with in vivo imaging was defined for macro-, meso- and microscale calcifications. Volume and thickness of aortic valve cusps, including the complete thickness distribution, were also determined. Moreover, changes in the cusp soft tissues were also visualized with microCT and confirmed by scanning electron microscopy images of the same sample. NF-LG-SAS cusps contained lower relative amount of calcifications than HG-SAS. Moreover, the number and size of calcified objects and the volume and thickness of the cusps were also lower in NF-LG-SAS cusps than in HG-SAS.ConclusionsThe application of high-resolution ex vivo microCT to stenotic aortic valve cusps provided a quantitative description of the general structure of the cusps and of the calcifications present in the cusp soft tissues. This detailed description could help in the future to better understand the mechanisms of AS
Toekomstverkenning MIRA 2009 Wetenschappelijk rapport verzuring
In dit wetenschappelijk rapport worden de jaargemiddelde deposities, sectorale bijdragen en de overschrijding van kritische lasten voor verzuring bepaald in Vlaanderen, en dit voor twee MIRA-scenarioâs, met name REF- scenario en EUR-scenario, voor de potentieel verzurende stoffen (NHx, NOy en SOx) voor de periode 2010 t.e.m. 2030. Het jaar 2006 werd beschouwd als referentiejaar. Er wordt ook bepaald wanneer herstel van bodemverzuring kan verwacht worden voor Vlaamse bosbodems
Diversity of Staphylococcus aureus Isolates in European Wildlife
Staphylococcus aureus is a well-known colonizer and cause of infection among
animals and it has been described from numerous domestic and wild animal
species. The aim of the present study was to investigate the molecular
epidemiology of S. aureus in a convenience sample of European wildlife and to
review what previously has been observed in the subject field. 124 S. aureus
isolates were collected from wildlife in Germany, Austria and Sweden; they
were characterized by DNA microarray hybridization and, for isolates with
novel hybridization patterns, by multilocus sequence typing (MLST). The
isolates were assigned to 29 clonal complexes and singleton sequence types
(CC1, CC5, CC6, CC7, CC8, CC9, CC12, CC15, CC22, CC25, CC30, CC49, CC59, CC88,
CC97, CC130, CC133, CC398, ST425, CC599, CC692, CC707, ST890, CC1956, ST2425,
CC2671, ST2691, CC2767 and ST2963), some of which (ST2425, ST2691, ST2963)
were not described previously. Resistance rates in wildlife strains were
rather low and mecA-MRSA isolates were rare (n = 6). mecC-MRSA (n = 8) were
identified from a fox, a fallow deer, hares and hedgehogs. The common cattle-
associated lineages CC479 and CC705 were not detected in wildlife in the
present study while, in contrast, a third common cattle lineage, CC97, was
found to be common among cervids. No Staphylococcus argenteus or
Staphylococcus schweitzeri-like isolates were found. Systematic studies are
required to monitor the possible transmission of human- and livestock-
associated S. aureus/MRSA to wildlife and vice versa as well as the possible
transmission, by unprotected contact to animals. The prevalence of S.
aureus/MRSA in wildlife as well as its population structures in different
wildlife host species warrants further investigation
A single natural nucleotide mutation alters bacterial pathogen host tropism
The capacity of microbial pathogens to alter their host tropism leading to epidemics in distinct host species populations is a global public and veterinary health concern. To investigate the molecular basis of a bacterial host-switching event in a tractable host species, we traced the evolutionary trajectory of the common rabbit clone of Staphylococcus aureus. We report that it evolved through a likely human-to-rabbit host jump over 40 years ago and that only a single naturally occurring nucleotide mutation was required and sufficient to convert a human-specific S. aureus strain into one that could infect rabbits. Related mutations were identified at the same locus in other rabbit strains of distinct clonal origin, consistent with convergent evolution. This first report of a single mutation that was sufficient to alter the host tropism of a microorganism during its evolution highlights the capacity of some pathogens to readily expand into new host species populations
Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3Â T
Cent scientifiques rĂ©pliquent Ă SEA (Suppression des ExpĂ©riences sur lâAnimal vivant) et dĂ©noncent sa dĂ©sinformation
La lutte contre la maltraitance animale est sans conteste une cause moralement juste. Mais elle ne justifie en rien la dĂ©sinformation Ă laquelle certaines associations qui sâen rĂ©clament ont recours pour remettre en question lâusage de lâexpĂ©rimentation animale en recherche
21e journée de cardiologie octobre 2013 : la maladie coronaire chez le diabétique: Qui depister?
Il existe aujourdâhui des outils efficaces pour faire le diagnostic de cardiopathie ischĂ©mique. Il est aussi Ă©tabli que lâexistence dâune ischĂ©mie myocardique silencieuse confĂšre un moins bon pronostic surtout si les lĂ©sions coronaires sont multiples et proximales. Cependant, le screening systĂ©matique de la maladie coronaire ne sâaccompagne pas dâune rĂ©duction des Ă©vĂšnements cardiovasculaires chez le patient diabĂ©tique. Les lignes de conduites sont dâailleurs inconsistantes voire parfois contradictoires lorsquâil sâagit de faire des recommandations sur le screening de la maladie coronaire dans cette population. Une des explications selon laquelle le screening nâimpacte pas le pronostic du patient diabĂ©tique est que la prĂ©valence du « patient diabĂ©tique asymptomatique porteur de lĂ©sions multiples et proximales » est faible et quâil est donc nĂ©cessaire dâĂ©valuer un trĂšs grand nombre de patients pour influencer le pronostic. Une autre explication vient peut-ĂȘtre du fait que le traitement proposĂ© (la revascularisation myocardique par exemple) nâest peut-ĂȘtre pas assez efficace (ou plus efficace que le traitement mĂ©dical optimal) pour prĂ©venir les Ă©vĂšnements. Enfin, une autre hypothĂšse consiste Ă penser que le traitement de revascularisation nâest pas proposĂ© systĂ©matiquement ou nâest pas proposĂ© aux patients qui en bĂ©nĂ©ficieraient le plus. Dans cette revue, nous reverrons briĂšvement la littĂ©rature qui concerne cette difficile question du screening de la maladie coronaire chez le patient diabĂ©tique et nous essayerons de dĂ©gager quelques recommandations
Are PDE5 inhibitors safe in patients with cardiovascular diseases? [Existe-t-il des risques liés à l'utilisation de iPDE5 chez les patients cardiaques?]
Les inhibiteurs de la phosphodiesterase 5 (iPDE-5) sont efficaces, bien tolĂ©rĂ©s et constituent un traitement de premiĂšre ligne de la dysfonction Ă©rectile. Les risques cardiovasculaires liĂ©s Ă leur utilisation sont faibles et notablement, il nâexiste aucune Ă©vidence scientifique qui les relie Ă un risque plus Ă©levĂ© dâinfarctus ou de dĂ©cĂšs cardiovasculaires. Puisquâil existe peu de donnĂ©es concernant la prescription dâiPDE-5 aprĂšs un Ă©vĂšnement cardiovasculaire rĂ©cent, il est logique de ne pas les prescrire endĂ©ans les 4 Ă 6 semaines qui suivent lâĂ©vĂšnement. Enfin, les iPDE-5 ne doivent jamais ĂȘtre prescrits aux patients traitĂ©s par dĂ©rivĂ©s nitrĂ©s. Un dĂ©lai de 24 heures doit ĂȘtre respectĂ© pour la prescription des dĂ©rivĂ©s nitrĂ©s aux patients qui ont pris du sildenafil ou du vardenafil. Un dĂ©lai de 48 heures sera respectĂ© pour le tadalafil
- âŠ